Advanced search
Publication Cover
mAbs Volume 14, 2022 - Issue 1
Submit an article Journal homepage
3,636
Views
8
CrossRef citations to date
0
Altmetric
Report

Quality comparability assessment of a SARS-CoV-2-neutralizing antibody across transient, mini-pool-derived and single-clone CHO cells

Gangling Xua Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, China National Institutes for Food and Drug Control, Beijing, ChinaView further author information
,
Chuanfei Yua Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, China National Institutes for Food and Drug Control, Beijing, ChinaView further author information
,
Wenbo Wanga Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, China National Institutes for Food and Drug Control, Beijing, ChinaView further author information
,
Cexiong Fub Shanghai Junshi Biosciences Co. Ltd, Shanghai, ChinaView further author information
,
Hongchuan Liub Shanghai Junshi Biosciences Co. Ltd, Shanghai, ChinaView further author information
,
Yanping Zhub Shanghai Junshi Biosciences Co. Ltd, Shanghai, ChinaView further author information
,
Yuan Lib Shanghai Junshi Biosciences Co. Ltd, Shanghai, ChinaView further author information
,
Chunyu Liua Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, China National Institutes for Food and Drug Control, Beijing, ChinaView further author information
,
Zhihao Fua Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, China National Institutes for Food and Drug Control, Beijing, ChinaView further author information
,
Gang Wua Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, China National Institutes for Food and Drug Control, Beijing, ChinaView further author information
,
Meng Lia Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, China National Institutes for Food and Drug Control, Beijing, ChinaView further author information
,
Sha Guoa Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, China National Institutes for Food and Drug Control, Beijing, ChinaView further author information
,
Xiaojuan Yua Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, China National Institutes for Food and Drug Control, Beijing, ChinaView further author information
,
Jialiang Dua Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, China National Institutes for Food and Drug Control, Beijing, ChinaView further author information
,
Yalan Yanga Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, China National Institutes for Food and Drug Control, Beijing, ChinaView further author information
,
Maoqin Duana Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, China National Institutes for Food and Drug Control, Beijing, ChinaView further author information
,
Yongfei Cuia Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, China National Institutes for Food and Drug Control, Beijing, ChinaView further author information
,
Hui Fengb Shanghai Junshi Biosciences Co. Ltd, Shanghai, ChinaView further author information
&
Lan Wanga Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, China National Institutes for Food and Drug Control, Beijing, ChinaCorrespondence[email protected]
View further author information
 show all
Article: 2005507 | Received 09 Sep 2021, Accepted 08 Nov 2021, Published online: 20 Dec 2021

References

  • Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L, et al. Addendum: a pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;588(7836):E6. doi:10.1038/s41586-020-2951-z.
  • Beigel J, Tomashek K, Dodd L, Mehta A, Zingman B, Kalil A, Hohmann E, Chu HY, Luetkemeyer A, Kline S, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020;383(19):1813–15. doi:10.1056/NEJMoa2007764.
  • Antwi-Amoabeng D, Kanji Z, Ford B, Beutler B, Riddle M, Siddiqui F. Clinical outcomes in COVID-19 patients treated with tocilizumab: an individual patient data systematic review. J Med Virol. 2020;92(11):2516–22. doi:10.1002/jmv.26038.
  • Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu N-H, Nitsche A, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–80.e8. doi:10.1016/j.cell.2020.02.052.
  • Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020;117(17):9490–96. doi:10.1073/pnas.2004168117.
  • Cao Y, Su B, Guo X, Sun W, Deng Y, Bao L, Zhu Q, Zhang X, Zheng Y, Geng C, et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Cell. 2020;182(1):73–84.e16. doi:10.1016/j.cell.2020.05.025.
  • Shi R, Shan C, Duan X, Chen Z, Liu P, Song J, Song T, Bi X, Han C, Wu L, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020;584(7819):120–24. doi:10.1038/s41586-020-2381-y.
  • Zost S, Gilchuk P, Case J, Binshtein E, Chen R, Nkolola J, Schäfer A, Reidy JX, Trivette A, Nargi RS, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020;584(7821):443–49. doi:10.1038/s41586-020-2548-6.
  • Yang L, Liu W, Yu X, Wu M, Reichert J, Ho M. COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19. Antibody Ther. 2020;3(3):205–12. doi:10.1093/abt/tbaa020.
  • Weinreich D, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Musser BJ, Soo Y, Rofail D, Im J, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021;384(3):238–51. doi:10.1056/NEJMoa2035002.
  • Chen P, Nirula A, Heller B, Gottlieb R, Boscia J, Morris J, Huhn G, Cardona J, Mocherla B, Stosor V, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med. 2021;384(3):229–37. doi:10.1056/NEJMoa2029849.
  • Bolisetty P, Tremml G, Xu S, Khetan A. Enabling speed to clinic for monoclonal antibody programs using a pool of clones for IND-enabling toxicity studies. mAbs. 2020;12(1):1763727. doi:10.1080/19420862.2020.1763727.
  • Kelley B. Developing therapeutic monoclonal antibodies at pandemic pace. Nat Biotechnol. 2020;38(5):540–45. doi:10.1038/s41587-020-0512-5.
  • Zhang Z, Chen J, Wang J, Gao Q, Ma Z, Xu S, Zhang L, Cai J, Zhou W. Reshaping cell line development and CMC strategy for fast responses to pandemic outbreak. Biotechnol Prog. 2021;37(5):e3186. doi:10.1002/btpr.3186.
  • Ambrogelly A, Gozo S, Katiyar A, Dellatore S, Kune Y, Bhat R, Sun J, Li N, Wang D, Nowak C, et al. Analytical comparability study of recombinant monoclonal antibody therapeutics. mAbs. 2018;10(4):513–38. doi:10.1080/19420862.2018.1438797.
  • Saunders K. Conceptual approaches to modulating antibody effector functions and circulation half-life. Front Immunol. 2019;10:1296. doi:10.3389/fimmu.2019.01296.
  • Liu L, Wang L, Zonderman J, Rouse J, Kim H. Automated, high-throughput infrared spectroscopy for secondary structure analysis of protein biopharmaceuticals. J Pharm Sci. 2020;109(10):3223–30. doi:10.1016/j.xphs.2020.07.030.
  • Wen J, Arthur K, Chemmalil L, Muzammil S, Gabrielson J, Jiang Y. Applications of differential scanning calorimetry for thermal stability analysis of proteins: qualification of DSC. J Pharm Sci. 2012;101(3):955–64. doi:10.1002/jps.22820.
  • Yu C, Zhang F, Xu G, Wu G, Wang W, Liu C, Fu Z, Li M, Guo S, Yu X, et al. Analytical similarity of a proposed biosimilar BVZ-BC to bevacizumab. Anal Chem. 2020;92(4):3161–70. doi:10.1021/acs.analchem.9b04871.
  • Li Q, Wu J, Nie J, Zhang L, Hao H, Liu S, Zhao C, Zhang Q, Liu H, Nie L, et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell. 2020;182(5):1284–94.e9. doi:10.1016/j.cell.2020.07.012.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.